NCT03318783View on ClinicalTrials.gov

Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

April 3, 2019

Study Completion Date

January 9, 2020

Conditions
Subarachnoid Hemorrhage, AneurysmalDelayed Cerebral IschemiaVasospasm, CerebralEndothelial Dysfunction
Interventions
DRUG

GSK2256294

GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.

DRUG

Placebo

Placebo will be administered in a single dose once daily enteral for a duration of 10 days.

Trial Locations (1)

97239

Oregon Health & Science University, Portland

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Foundation for Anesthesia Education and Research

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

Oregon Health and Science University

OTHER

NCT03318783 - Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial | Biotech Hunter | Biotech Hunter